For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240206:nRSF2106Ca&default-theme=true
RNS Number : 2106C Hargreaves Lansdown PLC 06 February 2024
HARGREAVES LANSDOWN PLC (HL): CHAIR SUCCESSION
06 February 2024
Further to its announcement on 29 November 2023 and following regulatory
approval of Alison Platt, the Board of HL is pleased to announce her
appointment to role of Chair of the Board and as a Non-Executive Director of
HL with effect from today, Tuesday 06 February 2024.
Other than the directorships disclosed above, there are no matters required by
paragraphs LR 9.6.13R (1) to (6) of the listing rules to be disclosed.
For further information please contact:
Hargreaves Lansdown Brunswick
James Found, Investor Relations Nick Cosgrove
07970 066 634 +44(0)207 404 5959
Danny Cox, Media Relations
07989 672 071
BIOGRAPHY
Alison Platt
Alison has extensive leadership experience across both private and listed
companies in the healthcare, financial services, retail and property, and
regulated sectors. She currently holds Chair positions at Dechra
Pharmaceuticals, a FTSE100 specialist veterinary products business, and
insurance company Ageas UK. She has also been a Non-Executive Director of
Tesco Plc since 2016.
Alison was CEO of Countrywide from 2014 - 2018 and prior to that she held
several senior roles at BUPA, including as Managing Director of its
International Development Markets business. She was previously a
Non-executive director of the Foreign and Commonwealth Office, a member of
Hampton-Alexander review steering group advising on diversity and inclusion
and Chair of Opportunity Now.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAGZGGZZVVGDZM